155 related articles for article (PubMed ID: 1464473)
1. Combined effects of synthetic lipid A analogs or bacterial lipopolysaccharide with glucosaminylmuramyl dipeptide on antitumor activity against Meth A fibrosarcoma in mice.
Shimizu T; Iwamoto Y; Yanagihara Y; Ikeda K; Achiwa K
Int J Immunopharmacol; 1992 Nov; 14(8):1415-20. PubMed ID: 1464473
[TBL] [Abstract][Full Text] [Related]
2. Combined effects of synthetic lipid A analogs and muramyl dipeptide on antitumor activity against Meth A fibrosarcoma in mice.
Shimizu T; Ohtsuka Y; Yanagihara Y; Itoh H; Nakamoto S; Achiwa K
Int J Immunopharmacol; 1991; 13(5):605-11. PubMed ID: 1783474
[TBL] [Abstract][Full Text] [Related]
3. [Immunostimulating effects of muramyl dipeptide, glucosaminyl muramyl dipeptide and their synthetic derivatives in vitro].
Rakhmilevich AL; Rakhimova MS; Andronova TM; Bovin NV
Antibiot Khimioter; 1989 Aug; 34(8):586-9. PubMed ID: 2589897
[TBL] [Abstract][Full Text] [Related]
4. Comparison of the biological activity of synthetic N-acylated asparagine or serine linked monosaccharide lipid A analogs.
Shimizu T; Iwamoto Y; Yanagihara Y; Ryoyama K; Suhara Y; Ikeda K; Achiwa K
Immunobiology; 1996; 196(4):321-31. PubMed ID: 9061373
[TBL] [Abstract][Full Text] [Related]
5. Antitumor activity against Meth A fibrosarcoma and biologic activities of synthetic monosaccharide analogs of lipid A in mice.
Shimizu T; Ohtsuka Y; Masuzawa T; Yanagihara Y; Itoh H; Nakamoto S; Achiwa K
Mol Biother; 1990 Jun; 2(2):110-4. PubMed ID: 2363854
[TBL] [Abstract][Full Text] [Related]
6. Biological activities and antitumor effects of synthetic lipid A analog linked N-acylated serine.
Shimizu T; Iida K; Iwamoto Y; Yanagihara Y; Ryoyama K; Asahara T; Ikeda K; Achiwa K
Int J Immunopharmacol; 1995 May; 17(5):425-31. PubMed ID: 7591367
[TBL] [Abstract][Full Text] [Related]
7. Muramyl peptides augment cytotoxic effect of tumor necrosis factor-alpha in combination with cytotoxic drugs on tumor cells.
Petrova EE; Valyakina TI; Simonova MA; Komaleva RL; Khaidukov SV; Makarov EA; Blokhin DY; Ivanov PK; Andronova TM; Nesmeyanov VA
Int Immunopharmacol; 2006 Sep; 6(9):1377-86. PubMed ID: 16846831
[TBL] [Abstract][Full Text] [Related]
8. Study on the reduction of chemotherapy induced neutropenia in mice using glucosaminylmuramyl dipeptide.
Armstrong NA; Bolton EJ; Morris DL
Arzneimittelforschung; 1999 Aug; 49(8):716-20. PubMed ID: 10483520
[TBL] [Abstract][Full Text] [Related]
9. Induction of a CD8+ cytotoxic T lymphocyte response to soluble antigen given together with a novel muramyl dipeptide adjuvant, N-acetyl-D-glucosaminyl-(beta 1-4)-N-acetylmuramyl-L-alanyl-D-isoglutamine (GMDP).
Hornung RL; Longo DL; Gowda VL; Kwak LW
Ther Immunol; 1995 Feb; 2(1):7-14. PubMed ID: 7553072
[TBL] [Abstract][Full Text] [Related]
10. The effect of glucosaminylmuramyl dipeptide injection to mice on the course of tuberculous infection and in vitro superoxide anion production.
Venkataprasad N; Ledger P; Ivanyi J
Int Arch Allergy Immunol; 1997 Sep; 114(1):23-9. PubMed ID: 9303327
[TBL] [Abstract][Full Text] [Related]
11. GMDP augments antitumor action of the CP/TNFalpha combination in vivo.
Petrova EE; Simonova MA; Komaleva RL; Britsina MV; Andronova TM; Nesmeyanov VA; Valyakina TI
Biomed Pharmacother; 2010 Apr; 64(4):240-8. PubMed ID: 19932583
[TBL] [Abstract][Full Text] [Related]
12. Endogenous tumour necrosis factor-alpha sensitise melanoma cells to glucosaminylmuramyl dipeptide.
Valyakina TI; Komaleva RL; Petrova EE; Malakhov AA; Shamborant OG; Andronova TM; Nesmeyanov VA
FEBS Lett; 1998 Apr; 426(3):373-6. PubMed ID: 9600269
[TBL] [Abstract][Full Text] [Related]
13. [Influence of liposomal glucosaminyl-muramyl dipeptide on superoxide and nitric oxide production by murine macrophages].
Parshykov OV; Stefanov OV
Ukr Biokhim Zh (1999); 2009; 81(5):74-82. PubMed ID: 20387650
[TBL] [Abstract][Full Text] [Related]
14. Comparison of biologic activities of synthetic lipopentapeptide analogs of bacterial lipoprotein in mice.
Shimizu T; Ohtsuka Y; Yanagihara Y; Kurimura M; Takemoto M; Achiwa K
Mol Biother; 1991 Mar; 3(1):46-50. PubMed ID: 2069759
[TBL] [Abstract][Full Text] [Related]
15. Mechanisms by which chemotherapeutic agents augment the antitumor effects of tumor necrosis factor: involvement of the pattern shift of cytokines from Th2 to Th1 in tumor lesions.
Inagawa H; Nishizawa T; Honda T; Nakamoto T; Takagi K; Soma G
Anticancer Res; 1998; 18(5D):3957-64. PubMed ID: 9854510
[TBL] [Abstract][Full Text] [Related]
16. The modulation of tumour necrosis factor-alpha, interleukin-1 alpha and glucose levels with GMDP and other analogues of muramyl dipeptide.
Adeleye TA; Moreno C; Ivanyi J; Aston R
APMIS; 1994 Feb; 102(2):145-52. PubMed ID: 8167010
[TBL] [Abstract][Full Text] [Related]
17. Biological activities of chemically synthesized N-acylated serine-linked lipid A analog in mice.
Shimizu T; Sugiyama K; Iwamoto Y; Yanagihara Y; Asahara T; Ikeda K; Achiwa K
Int J Immunopharmacol; 1994 Aug; 16(8):659-65. PubMed ID: 7989134
[TBL] [Abstract][Full Text] [Related]
18. Biological activity of chemically synthesized core sugar linked lipid A analog, heptose-(alpha 1----5)-2-keto-3-deoxyoctonic acid-(alpha 2----6)-2,3-diacyloxyacylglucosamine-4-phosphate.
Shimizu T; Ohtsuka Y; Yanagihara Y; Akamatsu S; Ikeda K; Achiwa K
Int J Immunopharmacol; 1992 Feb; 14(2):221-6. PubMed ID: 1624222
[TBL] [Abstract][Full Text] [Related]
19. Glucosaminylmuramyl dipeptide (GMDP) modulates endothelial cell activities in vitro but has no effect on angiogenesis in vivo.
Li CG; Kumar S; Ledger PW; Ponting JM; Carette M; Allan E
Inflamm Res; 1997 Sep; 46(9):348-53. PubMed ID: 9339390
[TBL] [Abstract][Full Text] [Related]
20. Regression of line-10 hepatocellular carcinoma by a less toxic cord factor analogue combined with L18-MDP or synthetic lipid A analogues.
Ishida H; Saiki I; Saito S; Hasegawa A; Kiso M; Azuma I
Vaccine; 1988 Oct; 6(5):440-4. PubMed ID: 3195200
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]
